[Pilot study on the efficacy of high doses of aldosterone and spirolactone derivatives in the treatment of multiple sclerosis].
D000328:Adult; D000450:Aldosterone / Q000008:administration & dosage* / Q000009:adverse effects; D001795:Blood Pressure Determination; D001835:Body Weight; D002908:Chronic Disease; D004562:Electrocardiography; D004569:Electroencephalography; D004573:Electrolytes / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D037102:Lectins; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010865:Pilot Projects; D013148:Spironolactone / Q000008:administration & dosage* / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D004573:Electrolytes; D037102:Lectins; D013148:Spironolactone; D000450:Aldosterone
Erste Erfahrungen über die Wirksamkeit hoher Dosen von Aldosteron und Spirolactone-Derivaten bei der Therapie der Multiplen Sklerose.